Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes

Open access

Abstract

OBJECTIVE: The Restoring Insulin Secretion (RISE) Adult Medication Study compared pharmacological approaches targeted to improve β-cell function in individuals with impaired glucose tolerance (IGT) or treatment-naive type 2 diabetes of <12 months duration. RESEARCH DESIGN AND METHODS: A total of 267 adults with IGT (n = 197, 74%) or recently diagnosed type 2 diabetes (n = 70, 26%) were studied. Participants were randomized to receive 12 months of metformin alone, 3 months of insulin glargine with a target fasting glucose <5 mmol/L followed by 9 months of metformin, 12 months of liraglutide combined with metformin, or 12 months of placebo. β-Cell function was assessed using hyperglycemic clamps at baseline, 12 months (on treatment), and 15 months (3 months off treatment). The primary outcome was β-cell function at 15 months compared with baseline. RESULTS: All three active treatments produced on-treatment reductions in weight and improvements in HbA1c compared with placebo; the greatest reductions were seen in the liraglutide plus metformin group. At 12 months, glucose-stimulated C-peptide responses improved in the three active treatment groups and were greatest in the liraglutide plus metformin group, but the arginine-stimulated incremental C-peptide response was reduced in the liraglutide plus metformin group. Despite on-treatment benefits, 3 months after treatment withdrawal there were no sustained improvements in β-cell function in any treatment group. CONCLUSIONS: In adults with IGT or recently diagnosed type 2 diabetes, interventions that improved β-cell function during active treatment failed to produce persistent benefits after treatment withdrawal. These observations suggest that continued intervention may be required to alter the progressive β-cell dysfunction in IGT or early type 2 diabetes.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc19-0556

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Cited by

See all 73

Metadata

Authors
The RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., Atkinson, K. M., Palmer, J. P., Utzschneider, K. M., Gebremedhin, T., Kernan-Schloss, A., Kozedub, A., Montgomery, B. K., Morse, E. J., Mather, K. J., Garrett, T., Hannon, T. S., Lteif, A., Patel, A., Chisholm, R., Moore, K., Pirics, V., Pratt, L., Nadeau, K. J., Gross, S., Zeitler, P. S., Williams, J., Cree-Green, M., Garcia Reyes, Y., Vissat, K., Arslanian, S. A., Brown, K., Guerra, N., Porter, K., Caprio, S., Savoye, M., Pierpont, B., Buchanan, T. A., Xiang, A. H., Trigo, E., Beale, E., Chow, T., Hendee, F. N., Katkhouda, N., Nayak, K., Martinez, M., Montgomery, C., Wang, X., Wu, J., Edelstein, S. L., Lachin, J. M., Tjaden, A. H., Marcovina, S., Harting, J., Albers, J., Hill, D., Savage, P. J., & Leschek, E. W.
Venue
Diabetes Care
Published
2019-06-09
Volume
42
Issue
9
Pages
1742-1751
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W4241784903
Cited by
73
References
40
Citations by year
2026: 5 · 2025: 6 · 2024: 5 · 2023: 11 · 2022: 16 · 2021: 18 · 2020: 9 · 2019: 3
FWCI
9.34
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases (U01DK-094406, U01DK-094430, U01DK-094431, U01DK-094438, U01DK-094467, P30DK-017047, P30DK-020595, P30DK-045735, P30DK-097512)
  • National Center for Advancing Translational Sciences (UL1TR-000430, UL1TR-001082, UL1TR-001108, UL1TR-001855, UL1TR-001857, UL1TR-001858, UL1TR-001863)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
beta-cell function, impaired glucose tolerance, type 2 diabetes, metformin, insulin glargine, liraglutide, treatment withdrawal, hyperglycemic clamp, C-peptide response, insulin secretion
MeSH terms
Insulin Glargine, Liraglutide, Adult, Arginine, B-Lymphocytes, Blood Glucose, Body Weight, C-Peptide, Diabetes Mellitus, Type 2, Fasting, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Metformin, Middle Aged, Glucose Intolerance, Withholding Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/dc19-0556
The paper
The RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., Atkinson, K. M., Palmer, J. P., Utzschneider, K. M., Gebremedhin, T., Kernan-Schloss, A., Kozedub, A., Montgomery, B. K., Morse, E. J., Mather, K. J., . . . Leschek, E. W. (2019). Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/dc19-0556

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.